Carboplatin combined with an alternating regimen of IV and oral vinorelbine is effective and well tolerated in patients with NSCLC,

By  

Inpharma, Vol. 1, Iss. 1445, 2004-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Docetaxel + carboplatin has the edge for advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Paclitaxel/vinorelbine similar to paclitaxel/carboplatin in NSCLC

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Pemetrexed + either carboplatin or oxaliplatin for advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1480-1481, 2005-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite